{"entity":{"id":"nct03091192","kind":"trial","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","aka":[],"tldr":"A phase 3 trial of Savolitinib and Sunitinib in renal cell carcinoma, run by AstraZeneca, active and no longer recruiting.","summary":"Savolitinib vs. Sunitinib in MET-driven PRCC. is a phase 3 interventional study registered as NCT03091192 by AstraZeneca, with 60 participants enrolled, started 2017-07-25 and due to reach its primary completion in 2019-08-18. Interventions recorded: Savolitinib and Sunitinib. Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03091192","url":"https://clinicaltrials.gov/study/NCT03091192"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["savolitinib","sunitinib"],"companies":["astrazeneca","hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03091192","phase":"3","setting":"A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)","sponsor":"AstraZeneca","enrolled":60,"outcomes":[]},"route":"/trials/nct03091192/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/"},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"}]}}